VA events were measured through devices to determine sustained ventricular tachycardia (SVT), non-sustained ventricular tachycardia (NSVT) and premature ventricular contraction (PVC).

SVT was defined as tachycardia lasting for ≥30 seconds or with hemodynamic disorder as determined by Holter and/or device.

NSVT was defined as recorded by Holter and/or device. PVC was defined as an early ventricular depolarization as determined by the device, and/or detected by Holter.

PVC data were not available for patients with single -lumen implantation type

Efficacy analysis set (EAS): Patients in the safety set who received at least one dose of ARNI and completed 12 months of complete treatment and follow-up or withdrew early after receiving at least one dose of ARNI. Only subjects who had this measurement index successfully paired (ACEI/ARB treatment and ARNI treatment) were included in the analysis.

To assess the number of occurrences of Ventricular arrhythmia (VA) events and Implantable cardioverter defibrillator (ICD) or Cardiac resynchronization therapy-defibrillator (CRT-D) shocks over 6 months of ACEI/ARB and 6 months of ARNI treatment.

PVC data were not available for patients with single-lumen implantation type

Efficacy analysis set (EAS): Patients in the safety set who received at least one dose of ARNI and completed 12 months of complete treatment and follow-up or withdrew early after receiving at least one dose of ARNI. Only subjects who had this measurement index successfully paired (ACEI/ARB treatment and ARNI treatment) were included in the analysis.

To compare the changes in Left Ventricular Ejection Fraction (LVEF) between ACEI/ARB and ARNI treatments.

LVEF is a measurement expressed as a percentage of how much blood in the left ventricle is pumped out with each contraction of the heart.

Efficacy analysis set (EAS): Patients in the safety set who received at least one dose of ARNI and completed 12 months of complete treatment and follow-up or withdrew early after receiving at least one dose of ARNI. Only participants with assessment of LVEF at 6 months of ACEI/ARB treatment and 6 months of ARNI treatment are included in the analysis.

To compare the changes in New York Heart Association (NYHA) level between ACEI/ARB and ARNI treatments.

NYHA classification is a subjective physician's assessment of heart failure patient's functional capacity and symptomatic status.

Class I - No limitation of physical activity. Class II - Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea (shortness of breath). Class III - Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, or dyspnea. Class IV - Unable to carry on any physical activity without discomfort. Symptoms of heart failure at rest. If any physical activity is undertaken, discomfort increases.

Efficacy analysis set (EAS): Patients in the safety set who received at least one dose of ARNI and completed 12 months of complete treatment and follow-up or withdrew early after receiving at least one dose of ARNI. Only participants with assessment of NYHA at 6 months of ACEI/ARB treatment and 6 months of ARNI treatment are included in the analysis.

To compare the changes in the N-Terminal prohormone of Brain Natriuretic Peptide(NT-proBNP) level between ACEI/ARB and ARNI treatments.

NT-proBNP are small proteins produced in large amounts when the heart senses it needs to work harder, such as in heart failure.

Efficacy analysis set (EAS): Patients in the safety set who received at least one dose of ARNI and completed 12 months of complete treatment and follow-up or withdrew early after receiving at least one dose of ARNI. Only participants with assessment of NT-proBNP at 6 months of ACEI/ARB treatment and 6 months of ARNI treatment are included in the analysis.

To compare the healthcare resource utilization of Heart Failure (HF) patients during ACEI/ARB and ARNI treatments

Efficacy analysis set (EAS): Patients in the safety set who received at least one dose of ARNI and completed 12 months of complete treatment and follow-up or withdrew early after receiving at least one dose of ARNI.

Once VA events were detected, implantable cardioverter defibrillator (ICD) could treat with high-energy shocks or Anti-tachycardia pacing (ATP). ATP consists of one or more trains of pacing stimuli, expressed as a percentage of the tachycardia cycle length for a given RR interval, from the onset of the preceding R wave.

Patients with sustained VA events would receive ICD or cardiac resynchronization therapy-defibrillator (CRT-D) shock therapy.

Efficacy analysis set (EAS): Patients in the safety set who received at least one dose of ARNI and completed 12 months of complete treatment and follow-up or withdrew early after receiving at least one dose of ARNI. Only subjects who had this measurement index successfully paired (ACEI/ARB treatment and ARNI treatment) were included in the analysis.